RESEARCH TRIANGLE PARK, NC, (December 2, 2020) – Med Aditus International, Inc. and Rymedi announce a cooperation agreement aimed at fostering access to high-quality medicines in sub-Saharan African countries while transforming the region’s emerging pharmaceutical sector into a world-class, sustainable ecosystem.
The agreement, in the form of a Memorandum of Understanding (MoU), formalizes the relationship between Med Aditus, a nonprofit that aspires to make affordable, quality-assured medicines available to patients in sub-Saharan Africa, and Rymedi, a Greenville, South Carolina-based company that employs technologies like blockchain and AI to capture, track, and share data to improve health and wellness outcomes. The MoU is set to strengthen and advance mutual interest in establishing a leading-edge pharmaceutical enterprise in several countries in sub-Saharan Africa for manufacturing quality-assured products that meet or exceed quality standards set by the world’s leading regulatory agencies: the U.S. Food & Drug Administration and the European Medicines Agency.
“The Med Aditus and Rymedi partnership will drive a revolution in sustainable, affordable, high-quality medicine supply worldwide. With appropriate process controls and organizational capability, the sub-Saharan region can manufacture the highest quality medicines,” said David Stefanich, CEO of Rymedi.
Access to quality medicines in sub-Saharan Africa is still lacking compared to other parts of the world, and many in the region struggle to afford even the basic medicines needed to prevent and treat infectious diseases. Across the region, demand for high-quality medicines far outweighs the locally manufactured supply and creates a heavy reliance on imported drugs. A large percentage of drugs in the market are counterfeit or substandard – contributing significantly to preventable deaths, illness, and drug resistance in the region.
“Med Aditus, in partnership with Rymedi, will make significant contributions to improving patients’ health outcomes in countries within sub-Saharan Africa, while also creating positive economic impact in these countries,” said Dhiren Thakker, President & CEO of Med Aditus.
Med Aditus and Rymedi will jointly explore further development of multiple innovative healthcare solutions, including blockchain technology, a form of distributed computing that uses advanced cryptography to ensure the integrity of data tracked across multiple parties, creating an immutable data record and secure access controls that protect privacy and sensitive information. For instance, Med Aditus manufacturing will use an automated quality management system powered by Rymedi’s proven blockchain technology platform, which will be deployed in conjunction with leading-edge modular continuous-flow pharmaceutical manufacturing technology – systems ideal for establishing operations in sub-Saharan Africa due to their ease of assembly, portability, and scalability.
In addition to deploying novel technologies, the companies plan to collaborate in developing and implementing innovative workforce education and training programs using virtual simulations, onsite training, and distance learning. These programs are designed to create and sustain a world-class pharmaceutical workforce in sub-Saharan Africa, producing quality medicines that people will be able to afford. In becoming part of the social fabric of the region through strategic partnerships with government, impact investors, and other stakeholders, Med Aditus has a clear opportunity to contribute to transforming the pharmaceutical manufacturing industry in sub-Saharan Africa.
“Med Aditus is playing the crucial ecosystem role of leveraging the latest technologies to bring the right pieces together for quality medicine production and distribution in Africa. Rymedi is proud to contribute our digital platform to automate quality management for highest quality product. It’s just a matter of time before African manufacturers are supplying both regional and global markets,” said Stefanich.
###
Med Aditus International, Inc. is a North Carolina, United States, nonprofit corporation; It is tax-exempt under the Internal Revenue Code Section 501 (c)(3).
For interviews or additional information about Med Aditus, please contact Chiara Canzi, Chief Communications Officer, at [email protected] and 434-249-5930.